About MDS+AML MATTER

To address the many challenges faced by members of the interdisciplinary care team involved in the diagnosis and treatment of patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), the American Society of Hematology (ASH), American Society for Clinical Pathology (ASCP), National Marrow Donor Program (NMDP), Oncology Nursing Society (ONS), and The France Foundation have partnered to create MDS+AML MATTER, a free education program that includes opportunities for both live and online learning.

The goals of the program are to provide guidance to the interdisciplinary MDS/AML care team on:

  • The optimal diagnosis and classification of both MDS and AML
  • Risk stratification and individualized treatment selection
  • Assessment of treatment responses
  • Monitoring for and mitigation of adverse events, and
  • Patient education regarding prognosis and treatment choices

Program components include:

Target Audience

The target audience for this program includes the entire interdisciplinary cancer care team involved in the diagnosis and management of patients with MDS and AML, including:

  • Hematologists
  • Oncologists
  • Hematopathologists
  • Pathologists
  • Physician assistants
  • Advanced practice nurses
  • Nurses
  • Hematopoietic cell transplantation clinicians
  • Other health care professionals

Steering Committee

Jessica Altman, MD, Committee Chair, Northwestern University Feinberg School of Medicine, Chicago, IL

Heidi Klepin, MD, Wake Forest Baptist Health, Winston Salem, NC

AnneMarie Block, PhD, Roswell Park Cancer Institute, Buffalo, NY

Linda J. Burns, MD, National Marrow Donor Program/Be The Match, Minneapolis, MN

Michael Linden, MD, PhD, University of Minnesota, Minneapolis, MN

Robert Paul Hasserjian, MD, Harvard Medical School, Boston, MA

Kirsten Roblee, BSN, RN, OCN, The James Cancer Hospital and Solove Research Institute, Columbus, OH

B. Douglas Smith, MD, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD

Support

These activities are supported by an independent medical education grant from Celgene.

back to top